.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Argus Health
Deloitte
US Army
Baxter
Daiichi Sankyo
Mallinckrodt
Covington
McKinsey

Generated: November 23, 2017

DrugPatentWatch Database Preview

QUDEXY XR Drug Profile

« Back to Dashboard

What is the patent landscape for Qudexy Xr, and when can generic versions of Qudexy Xr launch?

Qudexy Xr is a drug marketed by Upsher-smith Labs and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has seven patent family members in five countries and one supplementary protection certificate in one country.

The generic ingredient in QUDEXY XR is topiramate. There are twenty-six drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the topiramate profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-001Mar 11, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-005Mar 11, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-002Mar 11, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-001Mar 11, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-003Mar 11, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-005Mar 11, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-002Mar 11, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-005Mar 11, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-004Mar 11, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Upsher-smith Labs
QUDEXY XR
topiramate
CAPSULE, EXTENDED RELEASE;ORAL205122-004Mar 11, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for QUDEXY XR

Drugname Dosage Strength RLD Submissiondate
topiramateExtended-release Capsules25 mg, 50 mg, 100 mg, 150 mg, and 200 mgQudexy XR12/24/2015

International Patent Family for Tradename: QUDEXY XR

Country Document Number Estimated Expiration
Israel241053► Subscribe
South Korea20150132838► Subscribe
European Patent Office2968177► Subscribe
Canada2905011► Subscribe
South Korea20160124930► Subscribe
World Intellectual Property Organization (WIPO)2014143380► Subscribe
South Korea101674509► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: QUDEXY XR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB95/028United Kingdom► SubscribePRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
UBS
Fish and Richardson
Healthtrust
Chubb
Julphar
QuintilesIMS
Colorcon
Teva
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot